Liver Tumours, SARS CoV-2
Conditions
Brief summary
The project comprises two research lines. In the line 1, human monoclonal antibodies toward SARS-CoV-2 will be generate and characterized by in vitro functional tests. In the line 2, in vitro tests will be performed to evaluate the efficency of immune response mediated by antibodies direct to specific tumor molecules.
Interventions
None listed
Sponsors
Fondazione IRCCS Policlinico San Matteo di Pavia
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
Line 1: - Age \>18 at time of signing informed consent form * Signed informed consent form Line 2: - Primery liver tumor * Age \>18 at time of signing informed consent form * Signed informed consent form
Exclusion criteria
Line 1: - Active or history of neoplastic malignancy * Active autoimmune disease ongoing treatment with immunosuppressive therapy * Evidence of positive HIV, HCV, HBV test * Diabetes * Failure to sign informed consent form Line 2: - Concomitant diseases with life expectancy of less than 12 months * Chronic autoimmune or inflammatory diseases * Treatment with atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF therapies * Other extrahepatic neoplasms occurring or in the last 3 years except for tumors resected with curative intent and without evidence of relapse for \>3 years prior to signing informed consent and considered low risk of relapse * HIV infection * Failure to sign informed consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The efficiency of antibodies will be evaluated toward SARS-CoV-2 and liver primary tumor cells by functional in vitro tests. | From enrollement to 24 weeks |
Countries
Italy
Contacts
Primary ContactMario Mondelli, MD
Backup ContactBarbara Oliviero, Biologist
Outcome results
None listed